84 filings
8-K
ACXP
Acurx Pharmaceuticals Inc
15 May 24
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
7:13am
10-Q
2024 Q1
ACXP
Acurx Pharmaceuticals Inc
Quarterly report
14 May 24
4:05pm
ARS
2023 FY
ACXP
Acurx Pharmaceuticals Inc
29 Apr 24
Annual report to shareholders
4:15pm
DEFA14A
ACXP
Acurx Pharmaceuticals Inc
29 Apr 24
Additional proxy soliciting materials
4:12pm
DEF 14A
ACXP
Acurx Pharmaceuticals Inc
Definitive proxy
29 Apr 24
4:07pm
RW
t1uuo
17 Apr 24
Registration withdrawal request
4:05pm
FWP
fwo34mq9mrj048vv9
2 Apr 24
Free writing prospectus
7:31am
8-K
ar32q
18 Mar 24
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
4:15pm
S-8
67hfa63r36s
15 Mar 24
Registration of securities for employees
4:33pm
8-K
thriu hs8xbp3tfjwor
15 Nov 23
Entry into a Material Definitive Agreement
5:02pm
424B5
0p2w7ftrr7 qv908d
15 Nov 23
Prospectus supplement for primary offering
4:49pm
8-K
itinz
14 Nov 23
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
4:05pm
8-K
rwxf pm7ks8y1k65fq
3 Nov 23
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
4:05pm
8-K
h75ep5
2 Oct 23
Other Events
4:41pm
8-K
qox12jev7hbgbj8n
14 Aug 23
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
7:10am